For securing large, giant, and wide-neck aneurysms, conventional coil embolization has substantial limitations, such as incomplete occlusion, recanalization, and a high recurrence rate. To overcome these limitations, a novel paradigm was suggested and, as a result, flow-diverting device was developed. The flow-diverting device is an innovative and effective technique to allow securing of large, giant, and wide-neck aneurysms. In numerous studies, the flow-diverting device has shown better outcomes than coil embolization. However, the flow-diverting device has also some risks, including rupture of aneurysm, intracerebral hemorrhage, and ischemic stroke. In addition, with more experience, unexpected complications are also reported. 5)7) In the present case, we experienced a delayed ischemic stroke at 27 days after endovascular treatment. The patient had multiple aneurysms and, among them, we treated a large posterior communicating artery aneurysm using Pipeline TM Embolization Device. The patient was tolerable for 25 days, but then suddenly presented intermittent right hemiparesis. In the initial diffusion magnetic resonance imaging (MRI), there was no acute lesion; however, in the follow-up MRI, an acute ischemic stroke was found in the territory of anterior choroidal artery which was covered by Pipeline Embolization Device. We suspect that neo-intimal overgrowth or a tiny thrombus have led to this delayed complication. Through our case, we learned that the neurosurgeon should be aware of the possibility of delayed ischemic stroke after flow diversion, as well as, long-term close observation and follow-up angiography are necessary even in the event of no acute complications.
INTRODUCTION
The endovascular treatment of intracranial aneurysms has become an alternative technique of surgical clipping for 25 years. 9)18) However, coil embolization still has limitations, especially, in wide-neck, large, and giant aneurysm cases.
2)5)9)13) To overcome these limitations, the flow-diverting device was developed and introduced for the treatment of irresoluble aneurysms. 10) After the efficacy and safety of the flow-diverting de- vice has been demonstrated in several studies, it has generally been accepted as a new solution for large or wide-neck aneurysms. Although the flow-diverting device has low recanalization rate and low recurrence rate, it also has severe and unexpected complications, such as ischemic stroke, spontaneous rupture of aneurysm, intracerebral hemorrhage, and stent stenosis.
1)2)8)11)17)19)
Among these complications of the flow-diverting device, ischemic stroke due to thromboembolism and perforator occlusion is well-described and occurs most frequently. In previous reports, ischemic strokes were reported to occur in 2.5-13% of patients and most of the instances occurred during the endovascular treatment. 1)3)11)17) Ischemic stroke may result from insufficient antiplatelet therapy, stent wall thrombus formation and occlusion, parent artery occlusion or distal thromboembolic events. It should also be noted that this complication was more frequent in posterior circulation and giant aneurysm cases.
1)17)
In the present case, we observed a delayed ischemic stroke in the territory of the anterior choroidal artery which was covered by the flow-diverting device for the treatment of a large posterior communicating artery aneurysm.
CASE REPORT
A 56 year-old male with histories of cerebral palsy, craniotomy for head trauma, and acute myocardial infarction, presented at our hospital for incidentally de- ployed from the proximal MCA to the horizontal segment of the cavernous ICA, with covering the AChA and PCoA (Fig. 2) . Throughout the course of deployment, the combination of forward pressure and retraction technique was used to maximally attach PED to the ICA wall. The deployment of PED was successfully performed and, in the post-operative angiography, whole branch vessels were not interrupted by PED including PCoA, AChA (Fig. 3) . After embolization of the left side aneurysms, the femoral access site was closed with Perclose ProGlide (Abbott Vascular, Santa Clara, CA, USA) and, two days after the endovascular treatment, the patient was discharged with dual antiplatelet therapy, clopidogrel 75 mg, and aspirin 100mg daily, without neurologic deficit.
Dual antiplatelet therapy was continuously maintained and complications of the flow-diverting device were not observed during 25 days. However, 25 days after the endovascular treatment, the patient suddenly presented intermittent right hemiparesis. Although his symptom was not prominent in neurologic examination and he already had right hemiparesis due to previous cerebral palsy, we readmitted him for checking the diffusion magnetic resonance imaging (MRI). In the initial diffusion MRI which was checked at 25 days after the endovascular treatment, an ischemic stroke was not found, so we recommended TFCA for further evaluation. However, he refused more tests and management, because he had phobia about the additional brain exam. We comprehended his phobia because he already had histories of cerebral palsy and craniotomy for head trauma. Because the initial MRI was fine, we maintained dual antiplatelet therapy without additional medication and closely observed his symptoms in the hospital (Fig. 4) . However, as time passed, the patient complained of more frequent and worsening hemiparesis, so we rechecked diffusion MRI and MRA. In the second diffusion MRI which was checked at 27 days after the endovascular treatment, ischemic stroke in the territory of the left AChA was observed (Fig. 5 ) and his symptom, right hemiparesis, was aggravated to motor grade II and mRS score4. We recommended a follow-up TFCA to confirm the occlusion of AChA, but the patient re- Fig. 5 . Diffusion MRI scan at 27 days after the endovascular treatment. The patient's hemiparesis was aggravated, so we rechecked diffusion MRI again. In follow-up MRI, acute ischemic stroke was found in the territory of the left AChA. MRI = magnetic resonance imaging; AChA = anterior choroidal artery. Furthermore, its outcomes also show an excellent occlusion rate, a low recanalization rate, as well as acceptable morbidity and mortality as compared to coil embolization. The flow-diverting device has emerged as an answer to previously irresoluble aneurysms; however, it is not free from some complications. In recent studies, the complications of flow-diverting device, such as branch vessel and/or perforator occlusion, rupture of aneurysm, intracerebral hemorrhage (ICH), stent stenosis and even death were reported (Table 1) .
1-4)8)11)13)14)16)17)19)
Numerous single and multicenter studies demonstrated overall rates of adverse complications (Table   1) ; among these studies, intra-operative and post-operative rupture of aneurysm is a serious concern of flow-diverting device. Although, rupture of aneurysm was reported only 0.6-4%, however, once it occurs, it leads to serious sequelae. In Kallmesstudy, 11) the overall rupture rate was only 0.6%; however, the rupture rate was increased with the aneurysm size (giant 4.5%, large 0.6%, small aneurysm 0% Flow diversion-induced ICH is a more specific complication and leads to a significant morbidity and mortality. The incidence of ICH was 1-5% of the patients in several retrospective reports and the exact mechanism is unclear (Table 1) . However, dual antiplatelet therapy, hemorrhagic conversion of ischemic stroke, intra-operative hypertension, and altered pressure dynamics are suspected to be causes of ICH.
2)17)
As all of the above are related to blood pressure, blood pressure should be strictly controlled to prevent hemorrhagic complications.
Ischemic stroke has been reported to be a major complication accounting for 2.5-13.2% of all cases and a vast majority of strokes occurred within 30 days after the endovascular treatment. 
